T-cell immunotherapy for malignant glioma: Toward a combined approach

Current Opinion in Oncology

Volumn 22, Issue 6, 2010, Pages 604-610

  Dietrich, Pierre Yves ^a   Dutoit, Valérie ^a   Thang, Nhu Nam Tran ^a   Walker, Paul R ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

brain tumors; glioma; glioma vaccines; immunotherapy; T lymphocytes

Indexed keywords

ALPHAEBETA7 INTEGRIN; ANTISENSE OLIGONUCLEOTIDE; B7 ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; CHIMERIC ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DACLIZUMAB; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR VIII VACCINE; GAMMA INTERFERON; GRANZYME; INTEGRIN; STAT3 PROTEIN; T LYMPHOCYTE RECEPTOR; TEMOZOLOMIDE; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX6; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CELL HOMING; CELL LYSATE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG TARGETING; EFFECTOR CELL; FEASIBILITY STUDY; GENETIC ENGINEERING; GLIOBLASTOMA; HUMAN; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; MULTIMODALITY CANCER THERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECURRENT CANCER; REGULATORY T LYMPHOCYTE; REVIEW; SENSITIZATION; T CELL DEPLETION; T LYMPHOCYTE; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; BRAIN NEOPLASMS; GLIOMA; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES;

EID: 77958497844     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32833dead8     Document Type: Review

References (61)

1. Hoelzinger DB, Demuth T, Berens ME. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007; 99:1583-1593.
2. Bindea G, MlecnikB, Fridman WH, Pages F, et al. Natural immunity to cancer in humans. Curr Opin Immunol 2010; 22:215-222.
3. Walker PR, Prins RM, Dietrich PY, Liau LM. Harnessing T-cell immunity to target brain tumors. In: Van Meir EG, editor. CNS cancer: models, markers, prognostic factors, targets and therapeutic approaches. New York, USA: Humana Press; 2009. pp. 1165-1218.
4. Grauer OM, Wesseling P, Adema GJ. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol2009; 19:674-693.
5. Okada H, Kohanbash G, Zhu X, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol 2009; 29:1-42.
6. Perrin G, Schnuriger V, Quiquerez AL, et al. Astrocytoma infiltrating lymphocytes include major T cell clonal expansions confined to the CD8 subset. Int Immunol 1999; 11:1337-1350.
7. Castriconi R, Daga A, Dondero A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 2009; 182:3530-3539.
8. Bryant NL, Suarez-Cuervo C, Gillespie GY, et al. Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma. Neuro Oncol 2009; 11:357-367.
9. Yang I, Han SJ, Kaur G, Crane C, et al. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 2010; 17:6-10.
10. Calzascia T, Masson F, Berardino-Besson W, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by cross-presenting APCs. Immunity 2005; 22:175-184.
11. Fujita M, Zhu X, Ueda R, et al. Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells: significant roles of CXCL10. Cancer Res 2009; 69:1587-1595.
12. + T cell recruitment and low relative regulatory T cell infiltration. Cancer Immunol Immunother 2008; 57:1745-1756.
13. + T cells. J Immunol 2007; 179:845-853.
14. Tran Thang NN, Derouazi M, Philippin G, et al. Immune infiltration of sponta-neous mouse astrocytomas is dominated by immunosuppressive cells fromearly stages of tumor development. Cancer Res 2010; 70:4829-4839.
15. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol 2010; 12:351-365.
16. Fujita M, Scheurer ME, Decker SA, et al. Role of type-1 interferons in anti-glioma immunosurveillance: using mouse studies to guide examination of novel prognostic markers in humans. Clin Cancer Res 2010; 16:3409-3419.
17. Fecci PE, Mitchell DA, WhitesidesJF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66:3294-3302.
18. Hussain SF, Yang D, Suki D, et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol 2006; 8:261-279.
19. + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007; 83:145-152.
20. Maes W, Rosas GG, Verbinnen B, et al. DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma. Neuro Oncol 2009; 11:529-542.
21. Mitchell DA, Xie W, Schmittling R, et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol 2008; 10:10-18.
22. Lau SK, Chen YY, Chen WG, et al. Lack of association of cytomegalovirus with human brain tumors. Mod Pathol 2005; 18:838-843.
23. Beckhove P, Warta R, Lemke B, et al. Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest 2010; 120:2230-2242.
24. SchoorO, Hilf N, DutoitV, et al. IMA950: a novel multi-peptide cancer vaccine for treatment of glioblastoma [abstract].
25. Hambardzumyan D, Squatrito M, Holland EC. Radiation resistance and stemlike cells in brain tumors. Cancer Cell 2006; 10:454-456.
26. Dhodapkar MV. Immunity to stemness genes in human cancer. Curr Opin Immunol 2010; 22:245-250.
27. Schmitz M, Temme A, Senner V, et al. Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007; 96:1293-1301.
28. Ueda R, Ohkusu-Tsukada K, Fusaki N, et al. Identification of HLA-A2-and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stemcells for immunotherapy. Int J Cancer 2010; 126:919-929.
29. + cytolytic T cells. Cancer Res 2009; 69:8886-8893.
30. Van Gool S, Maes W, Ardon H, et al. Dendritic cell therapy of high-grade gliomas. Brain Pathol 2009; 19:694-712.
31. Yu JS, Liu G, Ying H, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004; 64:4973-4979.
32. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11:5515-5525.
33. Okada H, Lieberman FS, Walter KA, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med 2007; 5:67.
34. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008; 68:5955-5964.
35. Ebben JD, Rocque BG, Kuo JS. Tumour vaccine approaches for CNS malignancies: progress to date. Drugs 2009; 69:241-249.
36. Wheeler CJ, Das A, Liu G, Yu JS, et al. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004; 10:5316-5326.
37. Okada H. Brain tumor immunotherapy with type-1 polarizing strategies. Ann N Y Acad Sci 2009; 1174:18-23.
38. Choi BD, Archer GE, Mitchell DA, et al. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol 2009; 19:713-723.
39. + T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006; 24:5060-5069.
40. Sprangers B, Van Wijmeersch B, Fevery S, Waer M, et al. Experimental and clinical approaches for optimization of the graft-versus-leukemia effect. Nat Clin Pract Oncol 2007; 4:404-414.
41. Brenner MK, Heslop HE. Adoptive T cell therapy of cancer. Curr Opin Immunol 2010; 22:251-257.
42. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-2357.
43. Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normaltissues expressing cognate antigen. Blood 2009; 114:535-546.
44. Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimentaltumors. Clin Cancer Res 2010; 16:474-485.
45. Hau P, Jachimczak P, Bogdahn U. Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides. Expert Rev Anticancer Ther 2009; 9:1663-1674.
46. Bogdahn U, Mahapatra AK, Olyushin V, et al. Results of a phase Ib active-controlled study with AP 12009 for patients with recurrent or refractory anaplastic astrocytoma. J Clin Oncol 2008; 26 Suppl:abstract #2076.
47. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174:99-106.
48. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother 2009; 58:1627-1634.
49. Kim TG, Kim CH, Park JS, et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 2010; 17:143-153.
50. Heimberger AB, Sun W, Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol 2008; 10: 98-103.
51. YuH, Pardoll D, Jove R. STAT sincancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809.
52. Hussain SF, Kong LY, Jordan J, et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res 2007; 67:9630-9636.
53. Fujita M, Zhu X, Sasaki K, et al. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immuno-logical microenvironment in a murine intracranial glioma. J Immunol 2008; 180:2089-2098.
54. Calzascia T, Berardino-Besson W, Wilmotte R, et al. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol 2003; 171:2187-2191.
55. Pellegatta S, Poliani PL, Stucchi E, et al. Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol 2010; 12:377-388.
56. Okada H, Tsugawa T, Sato H, et al. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res 2004; 64:5830-5838.
57. Jack CS, Arbour N, Manusow J, et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005; 175:4320-4330.
58. Carpentier A, Metellus P, Ursu R, et al. Intracerebral administration of GpG oligonucleotide for patients with recurrent glioblastoma: a phase II study. Neuro Oncol 2010; 12:401-408.
59. Aymeric L, Apetoh L, Ghiringhelli F, et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70:855-858.
60. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73.
61. Ramakrishnan R, Assudani D, NagarajS, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy inmice. J Clin Invest 2010; 120:1111-1124.